Increased Severity of Ulcerative Colitis in the Terminal Phase of the Metabolic Syndrome

Ulcerative colitis is chronic immune-mediated disorder that affects primarily colonic mucosa. The metabolic syndrome has increasing global prevalence with a significant impact on biology of chronic diseases, such as ulcerative colitis. Today it is known that the metabolic syndrome attenuates severit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Tohoku journal of experimental medicine Jg. 254; H. 3; S. 171
Hauptverfasser: Jovanovic, Marina Milun, Jurisevic, Milena Milenko, Gajovic, Nevena Miroslav, Arsenijevic, Nebojsa Nikola, Jocic, Miodrag Vukasin, Jovanovic, Ivan Petar, Zdravkovic, Natasa Dragan, Djukic, Aleksandar Ljubodrag, Maric, Veljko Jovo, Jovanovic, Milan Milorad
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Japan 2021
Schlagworte:
Adult
Aged
Aged, 80 and over
Anti-Inflammatory Agents - therapeutic use
Colitis, Ulcerative - drug therapy
Colon
Female
Humans
Intestinal Mucosa
Male
Metabolic Syndrome - complications
Middle Aged
Young Adult
ulcerative colitis
immune response
disease severity
metabolic syndrome progression
ISSN:1349-3329, 1349-3329
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Ulcerative colitis is chronic immune-mediated disorder that affects primarily colonic mucosa. The metabolic syndrome has increasing global prevalence with a significant impact on biology of chronic diseases, such as ulcerative colitis. Today it is known that the metabolic syndrome attenuates severity of ulcerative colitis. Still, there is no evidence that different stages of metabolic syndrome alter the course of the ulcerative colitis. The aim of this study was to dissect out how progression of the metabolic syndrome impacted the biology of ulcerative colitis and severity of clinical presentation. Seventy-two patients (41 men and 31 women, 22-81 years old) were enrolled in this observational cross-sectional study. Concentrations of pro- and anti-inflammatory cytokines in serum and feces samples were measured and phenotype of colon infiltrating cells was analyzed. Patients in the terminal phase of the metabolic syndrome have clinically and pathohistologically more severe form of ulcerative colitis, which is followed by decreased concentrations of systemic galectin-1, increased values of systemic pro-inflammatory mediators and increased influx of lymphocytes in affected colon tissue. Our data suggest that reduced concentrations of galectin-1 and predomination of the pro-inflammatory mediators in patients with terminal stage of the metabolic syndrome enhance local chronic inflammatory response and subsequent tissue damage, and together point on important role of galectin-1 in immune response in ulcerative colitis patients with the metabolic syndrome.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:1349-3329
1349-3329
DOI:10.1620/tjem.254.171